Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors
Onconova Therapeutics' (ONTX) Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript August 10, 2023 Onconova Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.29. Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman: Sarah, excuse me, you are coming in and out […]
Onconova Therapeutics, Inc. (NASDAQ:NASDAQ:ONTX) Q2 2022 Earnings Conference Call August 11, 2022 16:30 ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Steve.